Long-term outcome of patients with locally resected high- and low-risk rectal carcinoid tumors

J Gastrointest Surg. 2014 Apr;18(4):768-73. doi: 10.1007/s11605-014-2468-6. Epub 2014 Feb 12.

Abstract

Background: Tumor size and lymphovascular invasion are known high-risk factors for lymph node and distant metastasis in patients with rectal carcinoid tumors. However, the optimal treatment for these tumors remains controversial.

Aim: The aim of this paper is to compare the outcome of local or radical resection between patients with high-risk (tumor size >10 mm or lymphovascular invasion) disease and those with low-risk (tumor size ≤10 mm, no lymphovascular invasion) disease.

Methods: Patients with rectal carcinoid tumors treated between January 1990 and March 2010 were identified retrospectively and classified into low- and high-risk groups.

Results: In total, 83 patients with rectal carcinoid tumors were included, 53 (64%) of whom were identified as low-risk and 30 (36%) as high-risk. Local resection was performed in 50 (60%) low-risk and 24 (29%) high-risk patients, and postoperative recurrence was observed in one (1%) of the high-risk patients who underwent local resection and one (11%) who underwent radical resection. No recurrence was observed in the low-risk group. Kaplan-Meier analysis of the patients who underwent local resection revealed that the 10-year disease-free survival rate was 100% in the low-risk group and 83.3% in the high-risk group.

Conclusions: There was no significant difference in outcome between local and radical resection.

MeSH terms

  • Blood Vessels / pathology
  • Carcinoid Tumor / pathology*
  • Carcinoid Tumor / surgery*
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Humans
  • Kaplan-Meier Estimate
  • Lymphatic Vessels / pathology
  • Male
  • Middle Aged
  • Neoplasm Invasiveness
  • Neoplasm Recurrence, Local / pathology*
  • Rectal Neoplasms / pathology*
  • Rectal Neoplasms / surgery*
  • Retrospective Studies
  • Risk Factors
  • Survival Rate
  • Time Factors
  • Tumor Burden